ArticleCurrent microbiology2025
Synergistic Interactions of Oxidized Amylose Silver Nanoparticles and Topically Applicable Antibiotics Against Staphylococcus aureus.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Staphylococcus aureus causes serious infections that are increasingly difficult to treat due to antibiotic resistance. In this study, we synthesized oxidized amylose silver nanoparticles (OAAgNPs) and evaluated their synergistic potential with topical antibiotics against multidrug-resistant (MDR) S. aureus. OAAgNPs were synthesized and characterized using spectroscopic and microscopic techniques, confirming their nanoscale structure (5-10 nm) and chemical composition. Antibacterial testing against 50 clinical MDR isolates showed that OAAgNPs alone inhibited bacterial growth. More importantly, combinations with gentamicin (GEN), ciprofloxacin, mupirocin (MUP), or fusidic acid (FA) significantly enhanced antibacterial efficacy. Synergy was strongest with GEN and consistently observed with MUP and FA-antibiotics for which such nanoparticle synergy has rarely been documented. Cytotoxicity assays on mammalian cells demonstrated low toxicity at therapeutically relevant concentrations. Overall, this study highlights the potential of OAAgNP-antibiotic combinations as a promising strategy for managing MDR skin infections. Further research toward clinical formulation development is warranted.
Indexed as
Identifiers
40682614What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.